Loading…
Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β‐Catenin Expression and Podocyte Epithelial‐Mesenchymal Transition
ABSTRACT Despite substantial progress in medical care, the morbidity rate of diabetic nephropathy (DN) remains high in patients with diabetes. Evidence suggests that connective tissue growth factor (CTGF) induced podocyte injury may contribute to DN and CTGF inhibition could reduce albuminuria. Howe...
Saved in:
Published in: | Journal of cellular biochemistry 2017-11, Vol.118 (11), p.3706-3712 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2687-47f9cd18162561e8c0a88607d43df4a459aa8fb89c5f1046fd72745bbc57a9a13 |
---|---|
cites | cdi_FETCH-LOGICAL-c2687-47f9cd18162561e8c0a88607d43df4a459aa8fb89c5f1046fd72745bbc57a9a13 |
container_end_page | 3712 |
container_issue | 11 |
container_start_page | 3706 |
container_title | Journal of cellular biochemistry |
container_volume | 118 |
creator | Dai, Hou‐Yong Ma, Li‐Na Cao, Yun Chen, Xiao‐Lan Shi, Hui Fan, Ya‐Ping Yang, Bin |
description | ABSTRACT
Despite substantial progress in medical care, the morbidity rate of diabetic nephropathy (DN) remains high in patients with diabetes. Evidence suggests that connective tissue growth factor (CTGF) induced podocyte injury may contribute to DN and CTGF inhibition could reduce albuminuria. However, to date the mechanisms involved in the effect of CTGF on podocyte injury have not been fully understood. The aim of this study is to investigate the effects of therapeutic CTGF antibody on glomerular β‐catenin expression and podocyte epithelial‐mesenchymal transition (EMT) in diabetic mice. C57BL/6J mice were randomly divided into three groups as the following: the control, DN, and DN treated by CTGF antibody group. DN was induced by a single intraperitoneal injection of streptozotocin and then CTGF antibody was administrated three times per week for 8 weeks. Urinary albumin excretion, mesangial proliferation and matrix deposition, and β‐catenin expression in glomeruli at mRNA and protein level were all increased in DN mice compared to that in the control. Besides, the development of EMT in podocytes from diabetic mice, demonstrated by the downregulation of nephrin and upregulation of desmin in glomeruli, was detected. Furthermore, blocking CTGF by specific antibody reduced albuminuria, prevented the overexpression of CTGF, as well as β‐catenin, in glomeruli and subsequently ameliorated podocyte EMT in DN mice. In summary, this study suggested that CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT, which might provide new insight into the mechanism of CTGF inhibition in the treatment of DN. J. Cell. Biochem. 118: 3706–3712, 2017. © 2017 Wiley Periodicals, Inc.
CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT. |
doi_str_mv | 10.1002/jcb.26017 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1884163832</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1939808714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2687-47f9cd18162561e8c0a88607d43df4a459aa8fb89c5f1046fd72745bbc57a9a13</originalsourceid><addsrcrecordid>eNp10UFu1DAUBmALUdFpYcEFkCU2dDGt7Tixs5yG6VDUQoUGtpHjvHQ8SuxgO4LsOAJX4AocpIfoScgwhQUSq7f59L_39CP0nJJTSgg72-rqlGWEikdoRkku5jzj_DGaEZGQOUsoO0RHIWwJIXmesCfokMlEEEbZDP248S6CjsZZ7BpcrFcXeGGjqVw94sWtMjZE_NqoCqLR-B30G-96FTcjNhZfGw34k1H4A9SDNvYWr1rXgR9a5fHdz_tv3wsVwU5y-bX3EMJui7I1vnG102MEvOxN3EBrVDvhawhg9WbsVIvXXtlgdmc9RQeNagM8e5jH6OPFcl28mV-9X10Wi6u5ZpmcXhZNrmsqacbSjILUREmZEVHzpG644mmulGwqmeu0oYRnTS2Y4GlV6VSoXNHkGL3a5_befR4gxLIzQUPbKgtuCCWVktMskQmb6Mt_6NYN3k7XlTRPckmkoHxSJ3ulvQvBQ1P23nTKjyUl5a63cuqt_N3bZF88JA5VB_Vf-aeoCZztwRfTwvj_pPJtcb6P_AURRqWM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1939808714</pqid></control><display><type>article</type><title>Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β‐Catenin Expression and Podocyte Epithelial‐Mesenchymal Transition</title><source>Wiley</source><creator>Dai, Hou‐Yong ; Ma, Li‐Na ; Cao, Yun ; Chen, Xiao‐Lan ; Shi, Hui ; Fan, Ya‐Ping ; Yang, Bin</creator><creatorcontrib>Dai, Hou‐Yong ; Ma, Li‐Na ; Cao, Yun ; Chen, Xiao‐Lan ; Shi, Hui ; Fan, Ya‐Ping ; Yang, Bin</creatorcontrib><description>ABSTRACT
Despite substantial progress in medical care, the morbidity rate of diabetic nephropathy (DN) remains high in patients with diabetes. Evidence suggests that connective tissue growth factor (CTGF) induced podocyte injury may contribute to DN and CTGF inhibition could reduce albuminuria. However, to date the mechanisms involved in the effect of CTGF on podocyte injury have not been fully understood. The aim of this study is to investigate the effects of therapeutic CTGF antibody on glomerular β‐catenin expression and podocyte epithelial‐mesenchymal transition (EMT) in diabetic mice. C57BL/6J mice were randomly divided into three groups as the following: the control, DN, and DN treated by CTGF antibody group. DN was induced by a single intraperitoneal injection of streptozotocin and then CTGF antibody was administrated three times per week for 8 weeks. Urinary albumin excretion, mesangial proliferation and matrix deposition, and β‐catenin expression in glomeruli at mRNA and protein level were all increased in DN mice compared to that in the control. Besides, the development of EMT in podocytes from diabetic mice, demonstrated by the downregulation of nephrin and upregulation of desmin in glomeruli, was detected. Furthermore, blocking CTGF by specific antibody reduced albuminuria, prevented the overexpression of CTGF, as well as β‐catenin, in glomeruli and subsequently ameliorated podocyte EMT in DN mice. In summary, this study suggested that CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT, which might provide new insight into the mechanism of CTGF inhibition in the treatment of DN. J. Cell. Biochem. 118: 3706–3712, 2017. © 2017 Wiley Periodicals, Inc.
CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT.</description><identifier>ISSN: 0730-2312</identifier><identifier>EISSN: 1097-4644</identifier><identifier>DOI: 10.1002/jcb.26017</identifier><identifier>PMID: 28370212</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Albumin ; Animals ; Antibodies - pharmacology ; beta Catenin - biosynthesis ; Catenin ; CONNECTIVE TISSUE GROWTH FACTOR ; Connective Tissue Growth Factor - antagonists & inhibitors ; Connective Tissue Growth Factor - metabolism ; Connective tissues ; Desmin ; Diabetes ; Diabetes mellitus ; Diabetic Nephropathies - metabolism ; Diabetic Nephropathies - pathology ; Diabetic Nephropathies - prevention & control ; DIABETIC NEPHROPATHY ; EPITHELIAL‐MESENCHYMAL TRANSITION ; Excretion ; Gene expression ; Inhibition ; Injury prevention ; Kidney Glomerulus - metabolism ; Kidney Glomerulus - pathology ; Male ; Mesenchyme ; Mice ; Morbidity ; mRNA ; Nephropathy ; PODOCYTE ; Podocytes - metabolism ; Podocytes - pathology ; Rodents ; Streptozocin ; β‐CATENIN</subject><ispartof>Journal of cellular biochemistry, 2017-11, Vol.118 (11), p.3706-3712</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2687-47f9cd18162561e8c0a88607d43df4a459aa8fb89c5f1046fd72745bbc57a9a13</citedby><cites>FETCH-LOGICAL-c2687-47f9cd18162561e8c0a88607d43df4a459aa8fb89c5f1046fd72745bbc57a9a13</cites><orcidid>0000-0001-7736-7108</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28370212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dai, Hou‐Yong</creatorcontrib><creatorcontrib>Ma, Li‐Na</creatorcontrib><creatorcontrib>Cao, Yun</creatorcontrib><creatorcontrib>Chen, Xiao‐Lan</creatorcontrib><creatorcontrib>Shi, Hui</creatorcontrib><creatorcontrib>Fan, Ya‐Ping</creatorcontrib><creatorcontrib>Yang, Bin</creatorcontrib><title>Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β‐Catenin Expression and Podocyte Epithelial‐Mesenchymal Transition</title><title>Journal of cellular biochemistry</title><addtitle>J Cell Biochem</addtitle><description>ABSTRACT
Despite substantial progress in medical care, the morbidity rate of diabetic nephropathy (DN) remains high in patients with diabetes. Evidence suggests that connective tissue growth factor (CTGF) induced podocyte injury may contribute to DN and CTGF inhibition could reduce albuminuria. However, to date the mechanisms involved in the effect of CTGF on podocyte injury have not been fully understood. The aim of this study is to investigate the effects of therapeutic CTGF antibody on glomerular β‐catenin expression and podocyte epithelial‐mesenchymal transition (EMT) in diabetic mice. C57BL/6J mice were randomly divided into three groups as the following: the control, DN, and DN treated by CTGF antibody group. DN was induced by a single intraperitoneal injection of streptozotocin and then CTGF antibody was administrated three times per week for 8 weeks. Urinary albumin excretion, mesangial proliferation and matrix deposition, and β‐catenin expression in glomeruli at mRNA and protein level were all increased in DN mice compared to that in the control. Besides, the development of EMT in podocytes from diabetic mice, demonstrated by the downregulation of nephrin and upregulation of desmin in glomeruli, was detected. Furthermore, blocking CTGF by specific antibody reduced albuminuria, prevented the overexpression of CTGF, as well as β‐catenin, in glomeruli and subsequently ameliorated podocyte EMT in DN mice. In summary, this study suggested that CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT, which might provide new insight into the mechanism of CTGF inhibition in the treatment of DN. J. Cell. Biochem. 118: 3706–3712, 2017. © 2017 Wiley Periodicals, Inc.
CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT.</description><subject>Albumin</subject><subject>Animals</subject><subject>Antibodies - pharmacology</subject><subject>beta Catenin - biosynthesis</subject><subject>Catenin</subject><subject>CONNECTIVE TISSUE GROWTH FACTOR</subject><subject>Connective Tissue Growth Factor - antagonists & inhibitors</subject><subject>Connective Tissue Growth Factor - metabolism</subject><subject>Connective tissues</subject><subject>Desmin</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic Nephropathies - metabolism</subject><subject>Diabetic Nephropathies - pathology</subject><subject>Diabetic Nephropathies - prevention & control</subject><subject>DIABETIC NEPHROPATHY</subject><subject>EPITHELIAL‐MESENCHYMAL TRANSITION</subject><subject>Excretion</subject><subject>Gene expression</subject><subject>Inhibition</subject><subject>Injury prevention</subject><subject>Kidney Glomerulus - metabolism</subject><subject>Kidney Glomerulus - pathology</subject><subject>Male</subject><subject>Mesenchyme</subject><subject>Mice</subject><subject>Morbidity</subject><subject>mRNA</subject><subject>Nephropathy</subject><subject>PODOCYTE</subject><subject>Podocytes - metabolism</subject><subject>Podocytes - pathology</subject><subject>Rodents</subject><subject>Streptozocin</subject><subject>β‐CATENIN</subject><issn>0730-2312</issn><issn>1097-4644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp10UFu1DAUBmALUdFpYcEFkCU2dDGt7Tixs5yG6VDUQoUGtpHjvHQ8SuxgO4LsOAJX4AocpIfoScgwhQUSq7f59L_39CP0nJJTSgg72-rqlGWEikdoRkku5jzj_DGaEZGQOUsoO0RHIWwJIXmesCfokMlEEEbZDP248S6CjsZZ7BpcrFcXeGGjqVw94sWtMjZE_NqoCqLR-B30G-96FTcjNhZfGw34k1H4A9SDNvYWr1rXgR9a5fHdz_tv3wsVwU5y-bX3EMJui7I1vnG102MEvOxN3EBrVDvhawhg9WbsVIvXXtlgdmc9RQeNagM8e5jH6OPFcl28mV-9X10Wi6u5ZpmcXhZNrmsqacbSjILUREmZEVHzpG644mmulGwqmeu0oYRnTS2Y4GlV6VSoXNHkGL3a5_befR4gxLIzQUPbKgtuCCWVktMskQmb6Mt_6NYN3k7XlTRPckmkoHxSJ3ulvQvBQ1P23nTKjyUl5a63cuqt_N3bZF88JA5VB_Vf-aeoCZztwRfTwvj_pPJtcb6P_AURRqWM</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Dai, Hou‐Yong</creator><creator>Ma, Li‐Na</creator><creator>Cao, Yun</creator><creator>Chen, Xiao‐Lan</creator><creator>Shi, Hui</creator><creator>Fan, Ya‐Ping</creator><creator>Yang, Bin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7736-7108</orcidid></search><sort><creationdate>201711</creationdate><title>Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β‐Catenin Expression and Podocyte Epithelial‐Mesenchymal Transition</title><author>Dai, Hou‐Yong ; Ma, Li‐Na ; Cao, Yun ; Chen, Xiao‐Lan ; Shi, Hui ; Fan, Ya‐Ping ; Yang, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2687-47f9cd18162561e8c0a88607d43df4a459aa8fb89c5f1046fd72745bbc57a9a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Albumin</topic><topic>Animals</topic><topic>Antibodies - pharmacology</topic><topic>beta Catenin - biosynthesis</topic><topic>Catenin</topic><topic>CONNECTIVE TISSUE GROWTH FACTOR</topic><topic>Connective Tissue Growth Factor - antagonists & inhibitors</topic><topic>Connective Tissue Growth Factor - metabolism</topic><topic>Connective tissues</topic><topic>Desmin</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic Nephropathies - metabolism</topic><topic>Diabetic Nephropathies - pathology</topic><topic>Diabetic Nephropathies - prevention & control</topic><topic>DIABETIC NEPHROPATHY</topic><topic>EPITHELIAL‐MESENCHYMAL TRANSITION</topic><topic>Excretion</topic><topic>Gene expression</topic><topic>Inhibition</topic><topic>Injury prevention</topic><topic>Kidney Glomerulus - metabolism</topic><topic>Kidney Glomerulus - pathology</topic><topic>Male</topic><topic>Mesenchyme</topic><topic>Mice</topic><topic>Morbidity</topic><topic>mRNA</topic><topic>Nephropathy</topic><topic>PODOCYTE</topic><topic>Podocytes - metabolism</topic><topic>Podocytes - pathology</topic><topic>Rodents</topic><topic>Streptozocin</topic><topic>β‐CATENIN</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dai, Hou‐Yong</creatorcontrib><creatorcontrib>Ma, Li‐Na</creatorcontrib><creatorcontrib>Cao, Yun</creatorcontrib><creatorcontrib>Chen, Xiao‐Lan</creatorcontrib><creatorcontrib>Shi, Hui</creatorcontrib><creatorcontrib>Fan, Ya‐Ping</creatorcontrib><creatorcontrib>Yang, Bin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dai, Hou‐Yong</au><au>Ma, Li‐Na</au><au>Cao, Yun</au><au>Chen, Xiao‐Lan</au><au>Shi, Hui</au><au>Fan, Ya‐Ping</au><au>Yang, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β‐Catenin Expression and Podocyte Epithelial‐Mesenchymal Transition</atitle><jtitle>Journal of cellular biochemistry</jtitle><addtitle>J Cell Biochem</addtitle><date>2017-11</date><risdate>2017</risdate><volume>118</volume><issue>11</issue><spage>3706</spage><epage>3712</epage><pages>3706-3712</pages><issn>0730-2312</issn><eissn>1097-4644</eissn><abstract>ABSTRACT
Despite substantial progress in medical care, the morbidity rate of diabetic nephropathy (DN) remains high in patients with diabetes. Evidence suggests that connective tissue growth factor (CTGF) induced podocyte injury may contribute to DN and CTGF inhibition could reduce albuminuria. However, to date the mechanisms involved in the effect of CTGF on podocyte injury have not been fully understood. The aim of this study is to investigate the effects of therapeutic CTGF antibody on glomerular β‐catenin expression and podocyte epithelial‐mesenchymal transition (EMT) in diabetic mice. C57BL/6J mice were randomly divided into three groups as the following: the control, DN, and DN treated by CTGF antibody group. DN was induced by a single intraperitoneal injection of streptozotocin and then CTGF antibody was administrated three times per week for 8 weeks. Urinary albumin excretion, mesangial proliferation and matrix deposition, and β‐catenin expression in glomeruli at mRNA and protein level were all increased in DN mice compared to that in the control. Besides, the development of EMT in podocytes from diabetic mice, demonstrated by the downregulation of nephrin and upregulation of desmin in glomeruli, was detected. Furthermore, blocking CTGF by specific antibody reduced albuminuria, prevented the overexpression of CTGF, as well as β‐catenin, in glomeruli and subsequently ameliorated podocyte EMT in DN mice. In summary, this study suggested that CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT, which might provide new insight into the mechanism of CTGF inhibition in the treatment of DN. J. Cell. Biochem. 118: 3706–3712, 2017. © 2017 Wiley Periodicals, Inc.
CTGF antibody protected podocytes against injury in DN mice by reducing β‐catenin overexpression and preventing podocyte EMT.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28370212</pmid><doi>10.1002/jcb.26017</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7736-7108</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0730-2312 |
ispartof | Journal of cellular biochemistry, 2017-11, Vol.118 (11), p.3706-3712 |
issn | 0730-2312 1097-4644 |
language | eng |
recordid | cdi_proquest_miscellaneous_1884163832 |
source | Wiley |
subjects | Albumin Animals Antibodies - pharmacology beta Catenin - biosynthesis Catenin CONNECTIVE TISSUE GROWTH FACTOR Connective Tissue Growth Factor - antagonists & inhibitors Connective Tissue Growth Factor - metabolism Connective tissues Desmin Diabetes Diabetes mellitus Diabetic Nephropathies - metabolism Diabetic Nephropathies - pathology Diabetic Nephropathies - prevention & control DIABETIC NEPHROPATHY EPITHELIAL‐MESENCHYMAL TRANSITION Excretion Gene expression Inhibition Injury prevention Kidney Glomerulus - metabolism Kidney Glomerulus - pathology Male Mesenchyme Mice Morbidity mRNA Nephropathy PODOCYTE Podocytes - metabolism Podocytes - pathology Rodents Streptozocin β‐CATENIN |
title | Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β‐Catenin Expression and Podocyte Epithelial‐Mesenchymal Transition |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T06%3A49%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protection%20of%20CTGF%20Antibody%20Against%20Diabetic%20Nephropathy%20in%20Mice%20Via%20Reducing%20Glomerular%20%CE%B2%E2%80%90Catenin%20Expression%20and%20Podocyte%20Epithelial%E2%80%90Mesenchymal%20Transition&rft.jtitle=Journal%20of%20cellular%20biochemistry&rft.au=Dai,%20Hou%E2%80%90Yong&rft.date=2017-11&rft.volume=118&rft.issue=11&rft.spage=3706&rft.epage=3712&rft.pages=3706-3712&rft.issn=0730-2312&rft.eissn=1097-4644&rft_id=info:doi/10.1002/jcb.26017&rft_dat=%3Cproquest_cross%3E1939808714%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2687-47f9cd18162561e8c0a88607d43df4a459aa8fb89c5f1046fd72745bbc57a9a13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1939808714&rft_id=info:pmid/28370212&rfr_iscdi=true |